$ASPI
ASP Isotopes Inc. Stock $aspi

$aspi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000147793223008461 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$433.0K	$0.00	$0.00
YoY Change
Cost Of Revenue	$294.1K	$0.00	$0.00
YoY Change
Gross Profit	$139.0K	$0.00	$0.00
YoY Change
Gross Profit Margin	32.09%
Selling, General & Admin	$4.097M	$3.710M	$4.095M
YoY Change	197.43%	207.04%	230.28%
% of Gross Profit	2948.06%
Research & Development	$65.17K	$239.2K	$252.9K
YoY Change	-30.99%	-67.91%	-43.36%
% of Gross Profit	46.9%
Depreciation & Amortization	$37.43K	$802.00	$167.00
YoY Change
% of Gross Profit	26.93%
Operating Expenses	$4.162M	$3.947M	$4.348M
YoY Change	182.78%	101.99%	157.83%
Operating Profit	-$4.023M	-$3.947M	-$4.348M
YoY Change		101.99%	425.09%
Interest Expense	-$67.73K	$0.00	$1.100K
YoY Change	-4676.35%	-100.0%	-24.14%
% of Operating Profit
Other Income/Expense, Net	-$85.50K	-$276.0K	$61.20K
YoY Change	-151.43%	9416.31%	7656.4%
Pretax Income	-$4.176M	-$4.220M	-$4.286M
YoY Change	220.24%	115.72%	154.42%
Income Tax	-$6.130K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.162M	-$4.222M	-$4.286M
YoY Change	219.16%	115.85%	154.42%
Net Earnings / Revenue	-961.21%
Basic Earnings Per Share		-$0.14	-$0.14
Diluted Earnings Per Share	-$0.10	-$0.14	-$0.14
COMMON SHARES
Basic Shares Outstanding	48.77M shares	37.39M shares	37.39M shares
Diluted Shares Outstanding		31.15M

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.908M	$2.290M	$3.626M
YoY Change	231.01%	430.62%	28.89%
Cash & Equivalents	$7.908M	$2.287M	$3.626M
Short-Term Investments
Other Short-Term Assets	$1.664M	$440.0K	$404.4K
YoY Change	82.26%	-61.82%	-45.62%
Inventory	$0.00
Prepaid Expenses
Receivables	$216.5K
Other Receivables	$721.6K
Total Short-Term Assets	$10.51M	$2.729M	$4.031M
YoY Change	218.29%	72.25%	13.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.97M	$8.347M	$7.735M
YoY Change	45.98%	7.48%	19.55%
Goodwill	$3.267M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.793M	$173.7K	$342.7K
YoY Change	1184.06%	32.15%
Total Long-Term Assets	$17.03M	$9.143M	$8.720M
YoY Change	85.25%	15.77%	34.78%
TOTAL ASSETS
Total Short-Term Assets	$10.51M	$2.729M	$4.031M
Total Long-Term Assets	$17.03M	$9.143M	$8.720M
Total Assets	$27.54M	$11.87M	$12.75M
YoY Change	120.4%	25.21%	27.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.112M	$402.0K	$670.1K
YoY Change	-17.94%	-65.24%	-23.8%
Accrued Expenses	$1.648M	$1.092M	$807.6K
YoY Change	356.15%	7.28%	22.09%
Deferred Revenue
YoY Change
Short-Term Debt	$470.4K	$30.00K	$33.85K
YoY Change	1289.66%	-11.37%	0.0%
Long-Term Debt Due	$61.94K
YoY Change
Total Short-Term Liabilities	$5.674M	$2.602M	$1.949M
YoY Change	193.02%	6.09%	7.34%
LONG-TERM LIABILITIES
Long-Term Debt	$207.1K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.720M	$630.0K	$648.2K
YoY Change	266.31%	-11.37%	-19.26%
Total Long-Term Liabilities	$2.927M	$630.0K	$648.2K
YoY Change	294.21%	-11.37%	-19.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.674M	$2.602M	$1.949M
Total Long-Term Liabilities	$2.927M	$630.0K	$648.2K
Total Liabilities	$11.25M	$3.232M	$2.597M
YoY Change	319.81%	2.18%	-0.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.84M	-$19.68M	-$15.45M
YoY Change	215.62%	214.89%
Common Stock	$489.2K	$383.5K	$373.9K
YoY Change	36.25%	27.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.30M	$8.639M	$10.15M
YoY Change
Total Liabilities & Shareholders Equity	$27.54M	$11.87M	$12.75M
YoY Change	120.4%	25.21%	27.16%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$4.162M	-$4.222M	-$4.286M
YoY Change	219.16%	115.85%	154.42%
Depreciation, Depletion And Amortization	$37.43K	$802.00	$167.00
YoY Change
Cash From Operating Activities	-$2.052M	-$660.0K	-$1.257M
YoY Change	138.09%	-4.94%	-9.15%
INVESTING ACTIVITIES
Capital Expenditures	$1.141M	$680.0K	$146.6K
YoY Change	26.46%	-63.0%	-91.54%
Acquisitions
YoY Change
Other Investing Activities	-$121.9K
YoY Change
Cash From Investing Activities	-$1.263M	-$680.0K	-$146.6K
YoY Change	39.96%	-63.0%	-91.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.895M	0.000	0.000
YoY Change	134.68%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.052M	-660.0K	-1.257M
Cash From Investing Activities	-1.263M	-680.0K	-146.6K
Cash From Financing Activities	8.895M	0.000	0.000
Net Change In Cash	5.580M	-1.340M	-1.403M
YoY Change	175.42%	-47.08%	428.41%
FREE CASH FLOW
Cash From Operating Activities	-$2.052M	-$660.0K	-$1.257M
Capital Expenditures	$1.141M	$680.0K	$146.6K
Free Cash Flow	-$3.194M	-$1.340M	-$1.403M
YoY Change	80.99%	-47.08%	-54.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	441820	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	2728625	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8346920	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	173664	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	401956	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1092328	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	33854	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48975	usd
CY2023Q3	us-gaap	Assets Assets	11871392	usd
	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-2093	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001921865
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35907127	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38348184	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Depreciation Depreciation	0	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	7233000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q3	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	0	shares
CY2022Q3	aspi	Restricted Stock RestrictedStock	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41555
	dei	Entity Registrant Name EntityRegistrantName	ASP Isotopes Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2618235
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1101 Pennsylvania Avenue NW
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	DC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20004
	dei	City Area Code CityAreaCode	202
	dei	Local Phone Number LocalPhoneNumber	756-2245
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01per share
	dei	Trading Symbol TradingSymbol	ASPI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48773276	shares
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	913005	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3302145	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8200595	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	622183	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	853889	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	139636	usd
CY2022Q4	us-gaap	Assets Assets	12496265	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1354903	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	361246	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	33854	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45903	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	882000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q3	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	142500	usd
CY2022Q4	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	140455	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2601613	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1936361	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	630292	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	742443	usd
CY2023Q3	us-gaap	Liabilities Liabilities	3231905	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2678804	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38348184	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35907127	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	383482	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	359071	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29219118	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16756426	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19676973	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7553066	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1286140	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	255030	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8639487	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9817461	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11871392	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12496265	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	239199	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	745461	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	699413	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1191901	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3707311	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1208319	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11319465	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2448091	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3946510	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1953780	usd
	us-gaap	Operating Expenses OperatingExpenses	12018878	usd
	us-gaap	Operating Expenses OperatingExpenses	3639992	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3946510	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1953780	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12018878	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639992	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-935	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q3	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-279425	usd
CY2022Q3	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-2903	usd
	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-109040	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	3452	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	453	usd
	us-gaap	Interest Income Other InterestIncomeOther	4946	usd
	us-gaap	Interest Income Other InterestIncomeOther	1907	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-275973	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2450	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105029	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-996	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4222483	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1956230	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12123907	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3640988	usd
CY2023Q3	aspi	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.14
CY2022Q3	aspi	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.06
	aspi	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.40
	aspi	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.13
CY2023Q3	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	31147749	shares
CY2022Q3	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	30107127	shares
	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	29954321	shares
	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	28642533	shares
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-4222483	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1956230	usd
	us-gaap	Profit Loss ProfitLoss	-12123907	usd
	us-gaap	Profit Loss ProfitLoss	-3640988	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-64644	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	150501	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1541170	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	275772	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4287127	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1805729	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13665077	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3365216	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9817461	usd
CY2023Q1	aspi	Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount	4493610	usd
CY2023Q1	aspi	Cancellation Of Common Stock Received In Exchange For Issuance Of Preferred Stock In Subsidiary Amount CancellationOfCommonStockReceivedInExchangeForIssuanceOfPreferredStockInSubsidiaryAmount	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	75570	usd
CY2023Q1	aspi	Issuance Of Restricted Common Stock Amount IssuanceOfRestrictedCommonStockAmount	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2144099	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1003853	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3615078	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	11911809	usd
CY2023Q2	aspi	Settlement Of Liabilities With Related Party SettlementOfLiabilitiesWithRelatedParty	626223	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2374686	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-472673	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4286346	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10153699	usd
CY2023Q3	aspi	Issuance Of Restricted Common Stock Amount IssuanceOfRestrictedCommonStockAmount	0	usd
CY2023Q3	aspi	Settlement Of Liabilities With Consultants Amount SettlementOfLiabilitiesWithConsultantsAmount	701125	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2071790	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-64644	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4222483	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8639487	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5997664	usd
CY2022Q1	aspi	Issuance Of Common Stock And Warrants Net Of Issuance Cost Amount IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostAmount	2090186	usd
CY2022Q1	aspi	Issuance Of Common Stock Upon Exercise Of Warrants Amount IssuanceOfCommonStockUponExerciseOfWarrantsAmount	0	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	20803	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-229257	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-857588	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7021808	usd
CY2022Q2	aspi	Issuance Of Common Stock Net Of Issuance Costs Of95723 Amount IssuanceOfCommonStockNetOfIssuanceCostsOf95723Amount	648626	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	210745	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	354528	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-827170	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7408537	usd
CY2022Q3	aspi	Issuance Of Restricted Common Shares Amount IssuanceOfRestrictedCommonSharesAmount	0	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	715410	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	150501	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1956230	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	6318218	usd
	us-gaap	Profit Loss ProfitLoss	-12123907	usd
	us-gaap	Profit Loss ProfitLoss	-3640988	usd
	us-gaap	Depreciation Depreciation	969	usd
	us-gaap	Depreciation Depreciation	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6590576	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	946958	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	669700	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	109040	usd
	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	2903	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	49173	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	51624	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-547373	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	132677	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-337612	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-48812	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-131408	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-298663	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	763695	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	712368	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	935039	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	882000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-30292	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120697	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3355171	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2077859	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1190157	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3570632	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1190157	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3570632	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3119560	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	506390	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	255965	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13046	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4493610	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2850549	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-51718	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2797942	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50617	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	275786	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2389140	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2953721	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2286805	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	431565	usd
	aspi	Settlement Of Liabilities With Related Party SettlementOfLiabilitiesWithRelatedParty	626223	usd
	aspi	Settlement Of Liabilities With Related Party SettlementOfLiabilitiesWithRelatedParty	0	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	124782	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	332879	usd
	aspi	Settlement Of Share Liability SettlementOfShareLiability	776695	usd
	aspi	Settlement Of Share Liability SettlementOfShareLiability	0	usd
	us-gaap	Profit Loss ProfitLoss	-12123907	usd
	us-gaap	Profit Loss ProfitLoss	-3640988	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2286805	usd
	aspi	Amount Received Description AmountReceivedDescription	$9,129,461 of aggregate proceeds received in October 2023 from the issuance of 9,952,510 shares of common stock at between $0.92 and $0.96 per share
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the three and nine months ended September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Our foreign subsidiaries held cash of approximately $187,515 and $38,000 as of September 30, 2023 and December 31, 2022, respectively, which is included in cash on the consolidated balance sheets. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S. If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.</p>
CY2023Q3	aspi	Federal Deposit Insurance FederalDepositInsurance	250000	usd
CY2023Q3	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	187515	usd
CY2022Q4	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	38000	usd
CY2023Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	142500	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	116200	usd
CY2022	aspi	Addition On Issuance Of Common Stock AdditionOnIssuanceOfCommonStock	174782	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-150527	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	140455	usd
	aspi	Hgu hgu	-776695	usd
	aspi	Addition On Issuance Of Common Stock AdditionOnIssuanceOfCommonStock	669700	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	109040	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	142500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8200595	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8347877	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	957	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	0	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8346920	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8200595	usd
CY2023Q3	us-gaap	Depreciation Depreciation	802	usd
	us-gaap	Depreciation Depreciation	969	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	33854	usd
	us-gaap	Loss On Contracts LossOnContracts	6800000	usd
CY2023Q3	us-gaap	Other Commitment OtherCommitment	7233000	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	6050000	usd
CY2023Q2	us-gaap	Loss Contingency Receivable Proceeds LossContingencyReceivableProceeds	626223	usd
CY2021Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.075	pure
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	952521	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	952521	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	622183	usd
CY2023Q3	aspi	Operating Lease Lease Liability Current OperatingLeaseLeaseLiabilityCurrent	48	usd
CY2023Q3	aspi	Operating Lease Lease Liability Noncurrent OperatingLeaseLeaseLiabilityNoncurrent	630292	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	29654	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	32452	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	88962	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	97357	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	24559	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	20585	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	70080	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	71343	usd
CY2023Q3	aspi	Remaining Lease Term Years RemainingLeaseTermYears	P7Y3M
CY2022Q3	aspi	Remaining Lease Term Years RemainingLeaseTermYears	P8Y3M
	aspi	Remaining Lease Term Years RemainingLeaseTermYears	P7Y3M
	aspi	Remaining Lease Term Years RemainingLeaseTermYears	P8Y3M
CY2023Q3	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.075	pure
CY2022Q3	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.075	pure
	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.075	pure
	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.075	pure
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	24125	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	100119	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	107628	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	115700	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	124377	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	431952	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	903901	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	224634	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	679267	usd
CY2023Q3	aspi	Lease Liability Current LeaseLiabilityCurrent	48975	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	630292	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	5154	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	18882	usd
CY2023Q3	aspi	Short Term Operating Lease Future Lease Payments ShortTermOperatingLeaseFutureLeasePayments	72039	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	100000	usd
CY2022Q1	aspi	Royalty Percentage On Sale Of Products RoyaltyPercentageOnSaleOfProducts	0.10	pure
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	354000	usd
CY2023Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	626223	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
	aspi	Exchange Of Common Shares Into Convertible Preferred Stock ExchangeOfCommonSharesIntoConvertiblePreferredStock	3000000	shares
CY2023Q3	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	2500	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38348184	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1559780	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3119560	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	255965	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	120491	shares
CY2022Q4	aspi	Fair Value Of Shares Issue FairValueOfSharesIssue	240982	usd
	aspi	Cash Director Fees CashDirectorFees	45000	usd
CY2023Q3	aspi	Restricted Stock RestrictedStock	6415874	shares
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	140455	usd
CY2023Q3	aspi	New Share Liabilities NewShareLiabilities	669700	usd
CY2023Q3	aspi	Market Adjustment MarketAdjustment	109040	usd
CY2023Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	776695	usd
CY2022Q3	us-gaap	Other Liabilities OtherLiabilities	142500	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.603	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0344	pure
	aspi	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P5Y6M
	aspi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6000000	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2901000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
	aspi	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P9Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	199500	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	86667	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.00
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814333	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
	aspi	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P8Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	105000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1501177	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.88
	aspi	Weighted Average Remaining Contractual Term In Years Exercisable WeightedAverageRemainingContractualTermInYearsExercisable	P8Y7M6D
CY2023Q3	aspi	Aggregate Intrinsic Value Exercisable AggregateIntrinsicValueExercisable	69609	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2814333	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.91
	aspi	Weighted Average Remaining Contractual Term In Years Vested Or Expected To Vest WeightedAverageRemainingContractualTermInYearsVestedOrExpectedToVest	P8Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	105000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2751000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.18
CY2023Q3	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	12616283	shares
CY2022Q3	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	2901000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1756750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	2340876	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.74
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6415874	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.58
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2071790	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	715410	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6590576	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	946958	usd
CY2023Q3	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	4222483	usd
CY2022Q3	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	1956230	usd
	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	12123907	usd
	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	3640988	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	31147749	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30107127	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29954321	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	28642533	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2814333	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2901000	shares
CY2023Q3	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	3386076	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
aspi-20230930_cal.xml	Edgar Link	unprocessable
0001477932-23-008461-index-headers.html	Edgar Link	pending
0001477932-23-008461-index.html	Edgar Link	pending
0001477932-23-008461.txt	Edgar Link	pending
0001477932-23-008461-xbrl.zip	Edgar Link	pending
aspi-20230930.xsd	Edgar Link	pending
aspi_10q.htm	Edgar Link	pending
aspi-20230930_def.xml	Edgar Link	unprocessable
aspi-20230930_lab.xml	Edgar Link	unprocessable
aspi-20230930_pre.xml	Edgar Link	unprocessable
aspi_ex311.htm	Edgar Link	pending
aspi_ex312.htm	Edgar Link	pending
aspi_ex321.htm	Edgar Link	pending
aspi_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
aspi_10q_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASPI
ASP Isotopes Inc. Stock $aspi

2023 Q4 Form 10-Q Financial Statement

#000147793223008461 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI ASP Isotopes Inc. Stock $aspi

2023 Q4 Form 10-Q Financial Statement

#000147793223008461 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI
ASP Isotopes Inc. Stock $aspi